{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T05:00:35Z","timestamp":1774328435845,"version":"3.50.1"},"reference-count":32,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T00:00:00Z","timestamp":1604534400000},"content-version":"unspecified","delay-in-days":4,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000009","name":"Foundation for the National Institutes of Health","doi-asserted-by":"publisher","award":["K24 AR066109"],"award-info":[{"award-number":["K24 AR066109"]}],"id":[{"id":"10.13039\/100000009","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["P30-AR072577"],"award-info":[{"award-number":["P30-AR072577"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002193","name":"Lupus Foundation of America","doi-asserted-by":"publisher","award":["Gary S. Gilkeson Career Development Award"],"award-info":[{"award-number":["Gary S. Gilkeson Career Development Award"]}],"id":[{"id":"10.13039\/100002193","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["Lupus Sci Med"],"accepted":{"date-parts":[[2020,9,26]]},"published-print":{"date-parts":[[2020,11]]},"abstract":"<jats:sec>\n                  <jats:title>Objective<\/jats:title>\n                  <jats:p>Given the increasing relevance of the ANA assay to classification of SLE and the uncertainty and variation surrounding different ANA assay performance, we compared the human epithelial type 2 (HEp-2) to mouse liver (ML) substrate in our local cohort and provided a review of the evidence for their use in autoimmune rheumatic diseases (ARDs).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Electronic health record data (2003\u20132008) were used to identify patients who had concurrent HEp-2 and ML ANA, and a diagnosis of SLE or other ARDs. We determined the agreement between HEp-2 and ML ANA regarding positivity, titre and pattern, and their predictors. Sensitivity of HEp-2 ANA, ML ANA, repeating HEp-2 ANA, and combining HEp-2 and ML ANA assays was assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>There were 961 patients with concurrent HEp-2 and ML ANA samples, including 418 SLEs. There was generally fair to moderate agreement in HEp-2 and ML ANA (kappa (\u03ba)=0.35\u20130.79), titres (\u03ba=0.34\u20130.79) and patterns (\u03ba=0.35\u20130.93). In SLE, the presence of anti-dsDNA antibodies was predictive of ANA agreement between HEp-2 and ML ANA (adjusted OR 6.27, 95%\u2009CI 1.45 to 27.20, p=0.01). The ANA sensitivity for most ARDs was highest when the HEp-2 test was repeated, followed by when the HEp-2 and ML ANA were combined and when only the HEp-2 or ML ANAs were used.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>In keeping with prior studies, we demonstrated that there was fair to moderate agreement between HEp-2 and ML assays in the largest comparison of HEp-2 and ML as substrates for ANA testing in various ARDs. Furthermore, ANA sensitivity was higher when the HEp-2 assay was repeated rather than combining HEp-2 and ML.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/lupus-2020-000431","type":"journal-article","created":{"date-parts":[[2020,11,5]],"date-time":"2020-11-05T16:05:37Z","timestamp":1604592337000},"page":"e000431","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":6,"title":["Different indirect immunofluorescence ANA substrate performance in a diagnostic setting of patients with SLE and related disorders: retrospective review and analysis"],"prefix":"10.1136","volume":"7","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3760-2737","authenticated-orcid":false,"given":"May Y","family":"Choi","sequence":"first","affiliation":[{"name":"Cumming School of Medicine, University of Calgary, Calgary, Alberta, Canada"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Cui","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karen","family":"Costenbader","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA"},{"name":"Harvard Medical School, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David","family":"Rydzewski","sequence":"additional","affiliation":[{"name":"Independent Scholar, Boston, MA, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa","family":"Bernhard","sequence":"additional","affiliation":[{"name":"Division of Clinical Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Schur","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2020,11,5]]},"reference":[{"key":"2025091512300880000_7.1.e000431.1","first-page":"607","article-title":"Disseminated lupus erythematosus, scleroderma, and dermatomyositis as manifestations of sensitization to DNA-protein. I. An immunohistochemical approach","volume":"34","author":"Bardawil","year":"1958","journal-title":"Am J Pathol"},{"key":"2025091512300880000_7.1.e000431.2","doi-asserted-by":"crossref","first-page":"324","DOI":"10.4049\/jimmunol.80.4.324","article-title":"Interaction of nuclei and globulin from lupus erythematosis serum demonstrated with fluorescent antibody","volume":"80","author":"Friou","year":"1958","journal-title":"J Immunol"},{"key":"2025091512300880000_7.1.e000431.3","first-page":"379","article-title":"Occurrence and characteristics of organ-specific antibodies in sera of aged persons","volume":"73","author":"Svec","year":"1969","journal-title":"J Lab Clin Med"},{"key":"2025091512300880000_7.1.e000431.4","doi-asserted-by":"publisher","DOI":"10.1016\/0091-6749(84)90517-7"},{"key":"2025091512300880000_7.1.e000431.5","doi-asserted-by":"publisher","DOI":"10.1136\/ard.47.8.634"},{"key":"2025091512300880000_7.1.e000431.6","doi-asserted-by":"publisher","DOI":"10.1136\/jcp.35.10.1118"},{"key":"2025091512300880000_7.1.e000431.7","doi-asserted-by":"publisher","DOI":"10.1093\/ajcp\/82.1.57"},{"key":"2025091512300880000_7.1.e000431.8","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)93485-9"},{"key":"2025091512300880000_7.1.e000431.9","first-page":"265","article-title":"Clinical comparison of cultured human epithelial cells and rat liver as substrates for the fluorescent antinuclear antibody test","volume":"12","author":"Miller","year":"1985","journal-title":"J Rheumatol"},{"key":"2025091512300880000_7.1.e000431.10","first-page":"137","article-title":"The prevalence of antinuclear antibodies in healthy young persons and adults, comparing rat liver tissue sections with HEp-2 cells as antigen substrate","volume":"12","author":"Forslid","year":"1994","journal-title":"Clin Exp Rheumatol"},{"key":"2025091512300880000_7.1.e000431.11","first-page":"610","article-title":"Comparing HEp-2 cell line with rat liver in routine screening test for antinuclear and antinucleolar autoantibodies in autoimmune diseases","volume":"45","author":"Prost","year":"1987","journal-title":"Ann Biol Clin"},{"key":"2025091512300880000_7.1.e000431.12","first-page":"651","article-title":"[The value of using HEP\/2 cells as compared to sections of rat liver in the detection of autoantibodies using indirect immunofluorescence in human pathology]","volume":"56","author":"Makni","year":"1989","journal-title":"Rev Rhum Mal Osteoartic"},{"key":"2025091512300880000_7.1.e000431.13","first-page":"442","article-title":"Ineffectiveness of rat liver tissues in the screening of connective tissue disease","volume":"25","author":"Aziz","year":"2004","journal-title":"Saudi Med J"},{"key":"2025091512300880000_7.1.e000431.14","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1128\/CDLI.7.1.72-78.2000","article-title":"Measurement of antinuclear antibodies: assessment of different test systems","volume":"7","author":"Kern","year":"2000","journal-title":"Clin Diagn Lab Immunol"},{"key":"2025091512300880000_7.1.e000431.15","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2009.127100"},{"key":"2025091512300880000_7.1.e000431.16","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1002\/art.40930","article-title":"2019 European League against Rheumatism\/American College of rheumatology classification criteria for systemic lupus erythematosus","volume":"71","author":"Aringer","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"2025091512300880000_7.1.e000431.17","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102400","article-title":"Ana as an entry criterion for the classification of SLE","volume":"18","author":"Pisetsky","year":"2019","journal-title":"Autoimmun Rev"},{"key":"2025091512300880000_7.1.e000431.18","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/j.autrev.2017.12.007","article-title":"The association of solid-phase assays to immunofluorescence increases the diagnostic accuracy for ANA screening in patients with autoimmune rheumatic diseases","volume":"17","author":"Bizzaro","year":"2018","journal-title":"Autoimmun Rev"},{"key":"2025091512300880000_7.1.e000431.19","doi-asserted-by":"publisher","DOI":"10.1002\/art.1780400909"},{"key":"2025091512300880000_7.1.e000431.20","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2018-214436"},{"key":"2025091512300880000_7.1.e000431.21","doi-asserted-by":"publisher","DOI":"10.1093\/labmed\/15.3.190"},{"key":"2025091512300880000_7.1.e000431.22","doi-asserted-by":"publisher","DOI":"10.1043\/0003-9985(2000)124&lt;0071:GFCUOT&gt;2.0.CO;2"},{"key":"2025091512300880000_7.1.e000431.23","doi-asserted-by":"publisher","DOI":"10.1172\/JCI105669"},{"key":"2025091512300880000_7.1.e000431.24","doi-asserted-by":"crossref","first-page":"annrheumdis-2017-212599","DOI":"10.1136\/annrheumdis-2017-212599","article-title":"Assay variation in the detection of antinuclear antibodies in the sera of patients with established SLE","volume":"77","author":"Pisetsky","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"2025091512300880000_7.1.e000431.25","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1002\/acr.23712","article-title":"Antinuclear Antibody\u2013Negative systemic lupus erythematosus in an international inception cohort","volume":"71","author":"Choi","year":"2019","journal-title":"Arthritis Care Res"},{"key":"2025091512300880000_7.1.e000431.26","doi-asserted-by":"publisher","DOI":"10.1002\/art.10561"},{"key":"2025091512300880000_7.1.e000431.27","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.jim.2018.05.014","article-title":"The clinical utility of anti-double-stranded DNA antibodies and the challenges of their determination","volume":"459","author":"Mummert","year":"2018","journal-title":"J Immunol Methods"},{"key":"2025091512300880000_7.1.e000431.28","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa021933"},{"key":"2025091512300880000_7.1.e000431.29","doi-asserted-by":"crossref","first-page":"e412","DOI":"10.1016\/S2665-9913(20)30084-9","article-title":"Utility of repeated antinuclear antibody tests: a retrospective database study","volume":"2","author":"Yeo","year":"2020","journal-title":"Lancet Rheumatol"},{"key":"2025091512300880000_7.1.e000431.30","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/cei.13402","article-title":"Longitudinal anti-nuclear antibody (ANA) seroconversion in systemic lupus erythematosus: a prospective study of Swedish cases with recent-onset disease","volume":"199","author":"Frodlund","year":"2020","journal-title":"Clin Exp Immunol"},{"key":"2025091512300880000_7.1.e000431.31","first-page":"1994","article-title":"Abnormal antinuclear antibody titers are less common than generally assumed in established cases of systemic lupus erythematosus","volume":"35","author":"Sj\u00f6wall","year":"2008","journal-title":"J Rheumatol"},{"key":"2025091512300880000_7.1.e000431.32","doi-asserted-by":"publisher","DOI":"10.1002\/art.24699"}],"container-title":["Lupus Science &amp; Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/lupus-2020-000431","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,15]],"date-time":"2025-09-15T19:30:20Z","timestamp":1757964620000},"score":1,"resource":{"primary":{"URL":"https:\/\/lupus.bmj.com\/lookup\/doi\/10.1136\/lupus-2020-000431"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2020,11,5]]},"published-print":{"date-parts":[[2020,11]]}},"alternative-id":["10.1136\/lupus-2020-000431"],"URL":"https:\/\/doi.org\/10.1136\/lupus-2020-000431","relation":{},"ISSN":["2053-8790"],"issn-type":[{"value":"2053-8790","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,11]]}}}